Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia

Published:2007-06 Issue:3 Volume:86 Page:208-211
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Nakayama Shin,Nagamura-Inoue Tokiko,Yokoyama Kazuaki,Ohno Nobuhiro,Ooi Jun,Takahashi Satoshi,Uchimaru Kaoru,Iseki Toru,Tojo Arinobu

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Reference18 articles.

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–2653.

2. Cortes J, Talpaz M, O’Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425–3432.

3. Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004;79:411–419.

4. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.

5. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res. 2004;28(Suppl 1):S71-S73.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological Status of Chronic Myelogenous Leukemia Patients with Complete Cytogenetic Response after Treatment;Tumori Journal;2015-05

2. Evaluation of blood parameters for the monitoring of erythrodermic cutaneous T-cell lymphoma;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2015-01

3. Evaluation von Laborparametern für das Monitoring bei erythrodermischen kutanen T-Zell-Lymphomen;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2015-01

4. Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor;Blood;2012-03-29

5. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia;Blood;2011-09-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3